Transvenous phrenic nerve stimulation improves apnoea indices, oxygenation, and quality of life in adults with central sleep apnoea, including those with heart failure.
The 2025 American Academy of Sleep Medicine Clinical Practice Guideline recognizes transvenous phrenic nerve stimulation as an evidence-based therapy for central sleep apnoea in adults, including heart failure patients. Current evidence indicates improvements in apnoea indices, oxygenation, and quality of life, though effects on mortality and hospitalisation require further prospective randomized data.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Transvenous phrenic nerve stimulation improves apnoea indices, oxygenation, and quality of life in adults with central sleep apnoea, including those with heart failure. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Transvenous phrenic nerve stimulation improves apnoea indices, oxygenation, and quality of life in adults with central sleep apnoea, including those with heart failure.
This conclusion is most relevant to: Adults with central sleep apnoea, including those with heart failure.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸The 2025 American Academy of Sleep Medicine Central Sleep Apnoea Guidelines and the Heart Failure Patient. (Cardiac failure review, 2026) —
How It Works
The proposed biological pathway:
- ▸Central sleep apnoea arises from instability in respiratory control, often associated with heart failure.
- ▸Transvenous phrenic nerve stimulation activates the diaphragm, restoring regular breathing patterns.
- ▸Improved ventilation reduces apnoea-hypopnoea events and improves oxygenation.
- ▸Result: Improved quality of life and reduced symptoms.
Who Might Benefit
Evidence fit by population:
- ▸Adults with central sleep apnoea, including those with heart failure
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Effect on mortality and hospitalisation lacks prospective randomized data.
- ▸Identification of patients with central sleep apnoea is often missed in clinical practice.
Frequently Asked Questions
What is transvenous phrenic nerve stimulation?▼
It is a therapy that uses a device to stimulate the phrenic nerve, causing the diaphragm to contract and restore normal breathing during sleep.
Is this therapy approved for heart failure patients with central sleep apnoea?▼
Yes, the 2025 AASM guideline recognizes it as an evidence-based therapy for adults with CSA, including those with heart failure.
What outcomes improve with this therapy?▼
Apnoea indices, oxygenation, and quality of life improve, but mortality and hospitalisation benefits are not yet confirmed.
Why is central sleep apnoea often missed in heart failure patients?▼
Symptoms may be attributed to heart failure itself, and routine screening for CSA is not always performed.
References
- 1.Kaplan SM, Berry RB, Abraham WT. “The 2025 American Academy of Sleep Medicine Central Sleep Apnoea Guidelines and the Heart Failure Patient..” Cardiac failure review, 2026. PMID: 42582605 DOI: 10.15420/cfr.2025.60